BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Biotech Beach

  Orexigen Therapeutics, Inc. Issued a Key Fourth U.S. Patent on Contrave(R)

  January 5, 2009

   · 

  4 min read
• Biotech Bay

  Lumenis, Inc. Announces An Evolution in Automated CO2 Laser Surgery

  January 5, 2009

   · 

  2 min read
• Deals

  Pfizer Inc. Chief Open to Acquisitions According to Report

  January 5, 2009

   · 

  1 min read
• Deals

  Northstar Neuroscience, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors

  January 5, 2009

   · 

  1 min read
• Drug Development

  Genmab A/S Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer; Phase III Did Not Fulfill a Criterion; Independent Data Monitoring Committee Has Recommended That the Trial Should Continue to Enroll Patients

  January 5, 2009

   · 

  1 min read
• Drug Development

  Genta Incorporated Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane in Clinical Development

  January 5, 2009

   · 

  6 min read
• Genetown

  Functional Vasculature Generated From Advanced Cell Technology’s Human Embryonic Stem Cells

  January 5, 2009

   · 

  1 min read
• Biotech Beach

  Medtech Insight and Windhover Conferences Announce their Upcoming “Investment In Innovation (In3) West” Conference March 2-4, 2009, Las Vegas, NV

  January 5, 2009

   · 

  1 min read
• Business

  PerkinElmer, Inc. And ID Business Solutions (IDBS) Announce Software Collaboration to Improve High Content Screening (HCS) Outcomes for Drug Discovery Research

  January 5, 2009

   · 

  1 min read
• Genetown

  Cubist Pharmaceuticals, Inc., the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile

  January 5, 2009

   · 

  1 min read